evipedia.ai
← Back

KY19382 for Health & Longevity

Created on 10/24/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

KY19382 is an experimental, laboratory-made relative of a plant pigment, built to switch on the signal that tells skin, hair follicles and cartilage to rebuild themselves; it is studied for hair regrowth, wound repair and bone lengthening. Findings in cells and mice are consistent, but no person has knowingly received it in a published study. There is no established dose, no approved product and no human safety information. (Full Review)

Protocol

Therapeutic protocol
None exists
Never dosed in a published human study; no human dose, concentration, frequency or duration established for any purpose
Animal hair-regrowth regimen
0.5 mM topical, once daily
300 μL in polyethylene glycol 400 on mouse skin for 14 or 28 days; an experimental parameter, not a human regimen
Animal wound-healing regimen
0.05 or 0.1 mM, daily
In polyethylene glycol 400, applied to the mouse wound until closure; an experimental parameter, not a human regimen
Time to effect
Hair regrowth
14 to 28 days
Of daily application, in mice; not established in humans
Wound healing
Within the first ten days
In mice; not established in humans

Benefits

Contraindications
  • People who are pregnant, planning pregnancy or breastfeeding
  • Children and adolescents with open growth plates
  • People with a current or previous cancer, or an inherited syndrome of this pathway such as familial adenomatous polyposis
  • People with liver disease
    •
Key Interactions
  • Lithium: caution (theoretical)
  • Other Wnt-pathway or GSK-3-directed agents (valproic acid, tideglusib): avoid (theoretical)
  • Drugs with liver toxicity (high-dose paracetamol, isoniazid, methotrexate): caution (theoretical)
  • CYP3A4 substrates (cholesterol-lowering statins, ciclosporin, oral contraceptives): caution (theoretical)
  • Over-the-counter products: caution (theoretical) with paracetamol, alcohol-containing preparations and topical products on the same area
  • Supplements: caution (theoretical) with indigo naturalis, woad, kava, concentrated green tea extract, comfrey
  • Supplements acting on the same pathway: caution (theoretical) with lithium orotate, berberine, curcumin
  • Other interventions: caution (theoretical) with microneedling, chemical peels, topical retinoids (tretinoin, adapalene)
    •

Risk & Side Effects

  • High:
  • Medium:
  • Low: Liver enzyme elevation; adverse events with indirubin-containing herbal preparations
    •
  • Speculative: Tumour promotion; cell toxicity above the working concentration; systemic absorption through skin
    •

Monitoring

Marker Target Why
ALT 7–55 U/L (standard reference range) Liver safety check
AST 8–48 U/L (standard reference range) Paired with ALT to tell liver from muscle as source
Total bilirubin 0.1–1.2 mg/dL (standard reference range) Marks impaired liver function

Cadence: Liver panel before any exposure as a baseline. No evidence-based cadence exists; common practice would be repeat liver enzymes at 4 weeks, then every 3 months while exposure continues, earlier if symptoms appear.

Qualitative Assessment

  • Local skin reaction at the application site: redness, itching, swelling or blistering
  • Any new or changing skin lesion in a treated area
  • Fatigue, nausea, loss of appetite, dark urine or yellowing of the eyes
  • Hair density and shedding, recorded photographically
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.